Evidence map›Paper›PMID 26085157›Full record

ArticleJournal of virology2015

Identification of the Receptor-Binding Domain of the Spike Glycoprotein of Human Betacoronavirus HKU1.

Zhaohui Qian, Xiuyuan Ou, Luiz Gustavo Bentim Góes, Christina Osborne, Anna Castano, Kathryn V Holmes, Samuel R Dominguez

Open access · greenAbstract read
In one paragraph

Article in Journal of virology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 2 pooled it
1.6field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 2 syntheses or guidelines pooled it, 56 citations in OpenAlex.

  1. Pooled it
  2. Frontiers in immunology · 2021
    Pooled it
  3. Article
  4. Article
  5. Article
  6. Structural proteins of human coronaviruses: what makes them different?Frontiers in cellular and infection microbiology · 2024
    Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Effective presence of antibodies against common human coronaviruses in immunoglobulin medicinal products.International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases · 2022
    Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 2 countries.

Zhaohui QianMOH Key Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Science, Beijing, China Department of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA zqian2013@sina.com Samuel.dominguez@ucdenver.edu.
Xiuyuan OuMOH Key Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Science, Beijing, China.
Luiz Gustavo Bentim GóesDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Christina OsborneDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA.
Anna CastanoDepartment of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Kathryn V HolmesDepartment of Microbiology, University of Colorado School of Medicine, Aurora, Colorado, USA.
Samuel R DominguezDepartment of Pediatrics, University of Colorado School of Medicine, Aurora, Colorado, USA zqian2013@sina.com Samuel.dominguez@ucdenver.edu.
University of Colorado Denver · USChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

University of Colorado Cancer Center Support Grant - Lung Cancer Patient-Derived Xenografts with Autologous Human Immune SystemsP30CA046934 · NCI · UNIVERSITY OF COLORADO DENVER · PI James V Degregori · 1988 to 2026
$117.0M
NCI NIH HHS P30 CA046934NCI NIH HHS P30CA046934PHS HHS 5K08-A1073525
6 · The paper itself

Abstract

unlabelledCoronavirus spike (S) glycoproteins mediate receptor binding, membrane fusion, and virus entry and determine host range. Murine betacoronavirus (β-CoV) in group A uses the N-terminal domain (NTD) of S protein to bind to its receptor, whereas the β-CoVs severe acute respiratory syndrome CoV in group B and Middle East respiratory syndrome CoV in group C and several α-CoVs use the downstream C domain in their S proteins to recognize their receptor proteins. To identify the receptor-binding domain in the spike of human β-CoV HKU1 in group A, we generated and mapped a panel of monoclonal antibodies (MAbs) to the ectodomain of HKU1 spike protein. They did not cross-react with S proteins of any other CoV tested. Most of the HKU1 spike MAbs recognized epitopes in the C domain between amino acids 535 and 673, indicating that this region is immunodominant. Two of the MAbs blocked HKU1 virus infection of primary human tracheal-bronchial epithelial (HTBE) cells. Preincubation of HTBE cells with a truncated HKU1 S protein that includes the C domain blocked infection with HKU1 virus, but preincubation of cells with truncated S protein containing only the NTD did not block infection. These data suggest that the receptor-binding domain (RBD) of HKU1 spike protein is located in the C domain, where the spike proteins of α-CoVs and β-CoVs in groups B and C bind to their specific receptor proteins. Thus, two β-CoVs in group A, HKU1 and murine CoV, have evolved to use different regions of their spike glycoproteins to recognize their respective receptor proteins. IMPORTANCE: Mouse hepatitis virus, a β-CoV in group A, uses the galectin-like NTD in its spike protein to bind its receptor protein, while HCoV-OC43, another β-CoV in group A, uses the NTD to bind to its sialic-acid containing receptor. In marked contrast, the NTD of the spike glycoprotein of human respiratory β-CoV HKU1, which is also in group A, does not bind sugar. In this study, we showed that for the spike protein of HKU1, the purified C domain, downstream of the NTD, could block HKU1 virus infection of human respiratory epithelial cells, and that several monoclonal antibodies that mapped to the C domain neutralized virus infectivity. Thus, the receptor-binding domain of HKU1 spike glycoprotein is located in the C domain. Surprisingly, two β-CoVs in group A, mouse hepatitis virus and HKU1, have evolved to use different regions of their spike glycoproteins to recognize their respective receptors.

Indexed as

Amino Acid SequenceAnimalsAntibodies, MonoclonalCell Line, TransformedChlorocebus aethiopsCoronavirusCoronavirus InfectionsDogsEpithelial CellsHEK293 CellsHumansMadin Darby Canine Kidney CellsMolecular Sequence DataMurine hepatitis virusProtein Structure, TertiaryReceptors, VirusAntibodies, MonoclonalReceptors, VirusSpike Glycoprotein, Coronavirus

Identifiers

PMID26085157
PMCPMC4524053
OpenAlexW1934043894

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.